Asset Details
Do you wish to reserve the book?
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
Do you wish to request the book?
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
2015
Overview
Background
Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β
2
-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.
Methods
We performed a retrospective analysis of data from a study (ClinicalTrials.gov registration: NCT00419744) comparing budesonide/formoterol 320/9 μg with formoterol 9 μg (both twice daily) in patients with moderate-to-very-severe COPD; reliever salbutamol 90 μg was provided. First occurrence of reliever use >4 (low), >10 (medium), and >20 (high) inhalations/day was assessed as a predictor of short-term (3-week) exacerbation risk. Mean daily reliever use in the week preceding the 2-month visit was investigated as a predictor of the long-term (10-month) exacerbation risk, using intervals of 2–5, 6–9, and ≥10 inhalations/day.
Results
Overall, 810 patients were included (61 % male; mean age 63.2 years; post-bronchodilator forced expiratory volume in 1 s 37.7 % of predicted). First occurrence of low, medium, or high reliever use was predictive of an exacerbation within the following 3 weeks; exacerbation risk increased significantly with increasing reliever use. Mean reliever use over 1 week was predictive of long-term exacerbation risk. Patients with mean use of 2–5, 6–9, and ≥10 inhalations/day exhibited 21 %, 67 %, and 135 % higher exacerbation rates, respectively, in the following 10 months, compared with <2 inhalations/day. Budesonide/formoterol was associated with lower short- and long-term exacerbation risk than formoterol in all reliever-use groups.
Conclusions
SABA reliever use is a predictor of short- and long-term exacerbation risk in moderate-to-very-severe COPD patients with a history of exacerbations receiving budesonide/formoterol or formoterol.
Publisher
Springer Science and Business Media LLC,BioMed Central,BioMed Central Ltd
Subject
/ Adult
/ Aged
/ Albuterol - administration & dosage
/ Bronchodilator Agents - administration & dosage
/ COPD
/ EFFICACY
/ Female
/ Forced Expiratory Volume - drug effects
/ Forced Expiratory Volume - physiology
/ Humans
/ Male
/ Medicine
/ MODERATE
/ Pneumology/Respiratory System
/ Pulmonary and Respiratory Medicine
/ Pulmonary Disease, Chronic Obstructive
/ Pulmonary Disease, Chronic Obstructive - drug therapy
/ Pulmonary Disease, Chronic Obstructive - physiopathology
/ Respiratory Medicine and Allergy
/ THERAPY
